GI MAP Test adds Cyclospora guidance for positive stool test results

GI MAP Test has launched a free educational resource for customers whose GI-MAP stool test detects Cyclospora. The service is meant to help people understand the result, know when to seek urgent care and prepare for follow-up treatment with a clinician.

Why it matters: - Cyclospora can cause symptoms that look like many other digestive infections, so a positive stool test can leave customers with urgent questions and no immediate clinician to explain the result. - The new resource is meant to reduce that gap and help customers act faster if symptoms worsen or medical attention is needed. - The guidance may also help customers make a more productive appointment with a licensed clinician.

What happened: - GI MAP Test launched a guidance resource for customers whose GI-MAP™ stool test detects Cyclospora. - The company announced the service on August 5, 2026. - The resource is sent by email with the customer’s test results only when Cyclospora is detected. - The service is available at no additional cost to eligible customers.

The details: - GI MAP Test provides access to the GI-MAP™ comprehensive stool test in the United States and Canada. - The GI-MAP™ is an at-home stool test analyzed by Diagnostic Solutions Laboratory, a CLIA-certified laboratory in the United States. - The test uses quantitative real-time PCR (qPCR) DNA analysis to detect and measure more than 85 gut targets from a single sample. - The panel includes bacterial, parasitic and viral pathogens, fungi and yeast, commensal bacteria, and markers of digestion, inflammation and immune function. - Cyclospora appears in the protozoan parasite section of the panel. - qPCR identifies specific DNA sequences rather than relying on culture or microscopy, which can help detect organisms present in small numbers. - Results are returned in approximately 14 to 16 days after the laboratory receives the sample and are reviewed by a practitioner. - The guidance resource explains what Cyclospora is and what a detected result may mean. - The resource describes common sources of contamination so customers can reduce the risk of repeat exposure. - The resource identifies symptoms that may require urgent medical attention rather than a routine appointment. - The resource sets general expectations for digestive recovery, including why symptoms can continue after treatment. - The company says the resource does not provide prescription medication instructions or dosing. - The company says the resource does not diagnose a condition, interpret symptoms in place of a medical evaluation or offer a self-treatment pathway. - Customers are directed to a licensed clinician for evaluation and treatment. - Madison Ordway, FDN-P, reviews the company’s educational content and said the goal is to help people arrive at their appointment prepared and understand why recovery can take time after treatment.

Between the lines: - The launch reflects a broader consumer-health problem: people can receive a lab result at home before they have a clinician available to explain next steps. - The resource is educational rather than therapeutic, which helps the company stay clear of prescribing or treatment claims while still adding post-test support. - The emphasis on urgent warning signs suggests the company wants customers to distinguish between waiting for an appointment and seeking immediate care. - Public health authorities, including the U.S. Centers for Disease Control and Prevention, describe Cyclospora as a microscopic single-celled parasite that infects the lining of the small intestine. - People become infected by consuming contaminated food or water. - Symptoms include watery diarrhea, loss of appetite and fatigue. - Treatment requires prescription therapy ordered by a qualified clinician.

What's next: - Eligible customers who ordered their GI-MAP™ test through GI MAP Test and received a Cyclospora-detected result will receive the resource automatically by email. - Customers who ordered through another practitioner, clinic, distributor or laboratory are directed back to the provider that placed the order. - Customers who are acutely unwell are advised not to wait for the resource and to contact a clinician or seek urgent medical care. - The GI-MAP™ test cannot be processed for residents of New York, New Jersey or Rhode Island because of state laboratory regulations. - More information is available in the company’s announcement.